Index
Grant: Purdue University — Imatinib Trial for Drug-Resistant Malaria (Coefficient Giving → Purdue University)
Verdictconfirmed95%
1 check · 4/9/2026Deterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Our claim
entire record- Grantee
- Purdue University
- Name
- Purdue University — Imatinib Trial for Drug-Resistant Malaria
- Amount
- $600,000
- Currency
- USD
- Date
- September 2022
- Notes
[Human Health and Wellbeing] Open Philanthropy recommended a grant of $600,000 over three years to Purdue University to support a phase III trial of imatinib, a drug previously approved to treat leukemia, to test its efficacy against drug-resistant strains of malaria in Vietnam. … expand
[Human Health and Wellbeing] Open Philanthropy recommended a grant of $600,000 over three years to Purdue University to support a phase III trial of imatinib, a drug previously approved to treat leukemia, to test its efficacy against drug-resistant strains of malaria in Vietnam. This research will be coordinated by Professor Philip Low, who previously organized a successful phase II trial of imatinib. This falls within our focus area of scientific research, specifically within our interest in advancing human health and wellbeing.
Source evidence
1 src · 1 checkconfirmed95%deterministic-row-match · 4/9/2026
- Name
- Purdue University — Imatinib Trial for Drug-Resistant Malaria
- Grantee
- Purdue University
- Focus Area
- Human Health and Wellbeing
- Amount
- $600,000.00
- Date
- September 2022
NoteDeterministic match: grantee, amount, date matched in source snapshot (2714 rows)
Case № NQJmbdmP86Filed 4/9/2026Confidence 95%